

**Title of Trial:** A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine

**Investigational Product:** safinamide

**Trial No.:** 27937

**Study Centers:** Not available

**Trial Initiation Date:** 04 May 2009

**Trial Completion Date:** 04 Jun 2009

**Development Phase:** Phase 3

**Publication (reference):** None

**Study Objectives:** Data not available

**Methodology:** Data not available

**Number of Subjects (Planned and Analyzed):** Data not available

**Diagnosis and Main Criteria for Inclusion/Exclusion:** Data not available

**Study Treatment:** Data not available

**Criteria for Evaluation:** Data not available

**Statistical Methods:** Data not available

**Results:** Data not available

**Conclusions:** Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

**Merck KGaA**

These results are supplied for informational purposes only.